Atlas Trials

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Clinical trial NCT03547154 · TERMINATED

Trial details

NCT number
NCT03547154
Sponsor
Merck Sharp & Dohme LLC
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Chronic Myelogenous Leukemia
Start date
1998-10-22
Primary completion
2001-02-20
Enrollment
344

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.